Eighteen nucleic acid therapeutics have been approved for treatment of various diseases in
the last 25 years. Their modes of action include antisense oligonucleotides (ASOs), splice …

More than 25 years after its discovery, the post-transcriptional gene regulation mechanism
termed RNAi is now transforming pharmaceutical development, proved by the recent FDA …

CRISPR technologies have begun to revolutionize T cell therapies; however, conventional
CRISPR-Cas9 genome-editing tools are limited in their safety, efficacy, and scope. To …

Drug delivery can be defined as the group of approaches a drug or pharmacologically active
agent can be transported to the target cell to treat disease or health issue. Conventional …

Small interfering RNA (siRNA) delivery by nanocarriers has been identified as a promising
strategy in the study and treatment of cancer. Short nucleotide sequences are synthesized …

The first therapeutic nucleic acid, a DNA oligonucleotide, was approved for clinical use in
1998. Twenty years later, in 2018, the first therapeutic RNA-based oligonucleotide was …

Small-molecule drug discovery has traditionally focused on occupancy of a binding site that
directly affects protein function, and this approach typically precludes targeting proteins that …

RNA interference (RNAi) is a unique treatment approach used to decrease a disease's
excessive gene expression, including cancer. SiRNAs may find and destroy homologous …

The highly specific induction of RNA interference-mediated gene knockdown, based on the
direct application of small interfering RNAs (siRNAs), opens novel avenues towards …

Cancer is one of the most complex diseases that has resulted in multiple genetic disorders
and cellular abnormalities. Globally, cancer is the most common health concern disease that …